Autolus Therapeutics Plc

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.65%337.000.0%$4575.72m
NVAXNovavax, Inc. 0.83%167.6379.4%$754.07m
BNTXBioNTech SE 5.45%275.310.0%$743.19m
AMGNAmgen, Inc. 0.73%204.611.4%$542.17m
SNSSSunesis Pharmaceuticals, Inc. -1.60%6.160.7%$430.61m
REGNRegeneron Pharmaceuticals, Inc. 1.38%550.972.7%$425.34m
GILDGilead Sciences, Inc. 0.68%66.351.0%$410.62m
CCXIChemoCentryx, Inc. 2.22%33.152.9%$393.75m
ILMNIllumina, Inc. 0.23%411.483.3%$375.53m
XLRNAcceleron Pharma, Inc. 0.69%174.205.3%$364.96m
VRTXVertex Pharmaceuticals, Inc. 1.99%184.391.9%$263.39m
BIIBBiogen, Inc. 0.45%270.931.7%$234.70m
OCGNOcugen, Inc. 1.38%8.370.0%$180.92m
XENEXenon Pharmaceuticals, Inc. -0.72%30.500.4%$170.52m
CRSPCRISPR Therapeutics AG 6.01%101.990.6%$163.47m

Company Profile

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.